Medicaid & Government Pricing Congress
Critical Policy Updates and Approaches to Effectively Contract, Report & Comply with State and Federal Healthcare Programs
Drug Pricing Transparency Congress
Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives & Strategic Best Practices for Compliance
Life Sciences Commercial Contracts & Chargebacks
Optimize Commercial Contract Models, Mitigate Revenue Leakage and Streamline Chargeback Excellence
IDN and Bio/Pharma Partnering Summit
Optimizing Strategic Partnerships to Improve Access and Patient Outcomes
Articles & Video
Can payment models for gene therapies evolve fast enough to keep up?
Gene therapy is revolutionizing healthcare, but can we revolutionize payment models in time to keep up?
HCEI and PIE: Is it time for pharma to be proactive in the argument over cost effectiveness?
How can drug manufacturers embracing the FDA's new HCEI and PIE guidance to engage payer customers early? Jeremy Schafer, PharmD, MBA, SVP, Precision for Value explores.
Federal and State Drug Pricing Regulation: What Laws and Changes Do We Anticipate in the Next 6-12 Months?
At Medicaid Drug Rebate Program in October 2021, Kristin Hicks, Partner at Arnold & Porter, presented a session looking at Federal and State Drug Pricing Regulation and exploring the laws and changes they anticipate over the next 6-12 months.
State Price Transparency Reporting (SPTR): Laws, Experience, Outlook, From Legal and Operational Perspectives | ClassOne Insight and Arent Fox
At Medicaid Drug Rebate Program in October 2021, Al Godley, VP Customer Solutions at ClassOne Insight and Stephanie Trunk, Partner at Arent Fox, presented a session titled 'State Price Transparency Reporting (SPTR): Laws, Experience, Outlook, From Legal and Operational Perspectives'. Watch the full session on-demand here.
340B: Living with the Adolescent Colossus | King & SpaldingBlueprint Medicines
"We should be on the lookout for the possible return of a Most Favored Nation reference pricing scheme" - Q&A with Katherine Chaurette, Blueprint MedicinesDrug Pricing
"There is always something interesting behind a state's motivation to control prescription drug costs" - Q&A with Porzio Life SciencesCOVID-19
REPORT: COVID-19 One Year On - Impacts on the Global Life Sciences Industry 2021Patient-Centric
What does it mean to be patient centered in health economics?
Let us help you engage qualified decision makers in need of experts and services to navigate global life science regulation. Share your strategy and plans so we can help you identify the best opportunities to reach your objectives. Our team will collaborate with you to develop a bespoke program tailored to your unique needs.
To find out more about sponsor opportunities, contact Derek Tagliarino:
email@example.com | +1-339-298-2206
All opportunities can be customised to align with your needs and budget. Examples may include:
- Exhibition space
- Speaking slots and onsite video interviews
- High-impact branding and messaging
- Private/public hosted events (lunches, breakfasts, and receptions)
- Custom digital campaigns
Sign up for the monthly Pricing & Contracting newsletter
Get the latest content and updates straight to your inbox